Expansion Into New Modalities — During The Pandemic And Beyond
Source: Rentschler Biopharma

Supporting both German mRNA-based COVID-19 vaccine developers BioNTech SE and CureVac N.V., Rentschler Biopharma SE has not only expanded into the promising field of RNA manufacturing. In this interview, Federico Pollano, Senior Vice President, Global Business Development, speaks about the company’s recent expansion into the cell and gene therapy market.
VIEW THE Q&A!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of BioProcess Online? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
Rentschler Biopharma
This website uses cookies to ensure you get the best experience on our website. Learn more